Thomas J. Saphner

7.3k total citations · 2 hit papers
31 papers, 1.9k citations indexed

About

Thomas J. Saphner is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Thomas J. Saphner has authored 31 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Thomas J. Saphner's work include Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (8 papers) and Advanced Breast Cancer Therapies (6 papers). Thomas J. Saphner is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Breast Cancer Treatment Studies (8 papers) and Advanced Breast Cancer Therapies (6 papers). Thomas J. Saphner collaborates with scholars based in United States, Canada and Peru. Thomas J. Saphner's co-authors include D C Tormey, Richard Gray, Antonio C. Wolff, George W. Sledge, Joseph A. Sparano, Nancy E. Davidson, Edith A. Perez, Sunil Badve, William C. Wood and Molin Wang and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Thomas J. Saphner

29 papers receiving 1.8k citations

Hit Papers

Prognostic Value of Tumor-Infiltrating Lymphocytes in Tri... 2014 2026 2018 2022 2014 2023 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
    2014 953 citations Sylvia Adams, Robert J. Gray et al. Journal of Clinical Oncology profile →
  2. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update
    2023 251 citations Antonio C. Wolff, Mark R. Somerfield et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas J. Saphner United States 12 1.3k 544 432 405 211 31 1.9k
Grazyna Liebérman United States 7 1.1k 0.8× 238 0.4× 114 0.3× 404 1.0× 537 2.5× 9 1.7k
Lorenzo Gianni Italy 21 1.2k 0.9× 600 1.1× 124 0.3× 526 1.3× 405 1.9× 91 2.0k
Robert S. Lavey United States 25 724 0.5× 367 0.7× 139 0.3× 498 1.2× 520 2.5× 52 2.5k
Susan C. Guba United States 22 1.3k 1.0× 350 0.6× 346 0.8× 784 1.9× 675 3.2× 49 2.4k
H. Richard Alexander United States 23 581 0.4× 173 0.3× 206 0.5× 343 0.8× 477 2.3× 63 1.9k
Cristian Lolli Italy 19 578 0.4× 331 0.6× 130 0.3× 761 1.9× 274 1.3× 88 1.4k
Lina Tang China 23 831 0.6× 171 0.3× 71 0.2× 645 1.6× 446 2.1× 73 1.6k
Stefan Diem Switzerland 17 2.2k 1.7× 219 0.4× 625 1.4× 629 1.6× 294 1.4× 31 2.6k
Pınar Saip Türkiye 21 606 0.5× 354 0.7× 63 0.1× 520 1.3× 288 1.4× 115 1.6k
Wei‐Xiang Qi China 24 1.1k 0.9× 227 0.4× 60 0.1× 940 2.3× 426 2.0× 109 2.1k

Countries citing papers authored by Thomas J. Saphner

Since Specialization
Citations

This map shows the geographic impact of Thomas J. Saphner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas J. Saphner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas J. Saphner more than expected).

Fields of papers citing papers by Thomas J. Saphner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas J. Saphner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas J. Saphner. The network helps show where Thomas J. Saphner may publish in the future.

Co-authorship network of co-authors of Thomas J. Saphner

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas J. Saphner. A scholar is included among the top collaborators of Thomas J. Saphner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas J. Saphner. Thomas J. Saphner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wolff, Antonio C., Mark R. Somerfield, Mitch Dowsett, et al.. (2023). Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO–College of American Pathologists Guideline Update. Journal of Clinical Oncology. 41(22). 3867–3872. 251 indexed citations breakdown →
3.
Sparano, Joseph A., Robert J. Gray, Della Makower, et al.. (2023). Abstract GS1-05: Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates. Cancer Research. 83(5_Supplement). GS1–5. 4 indexed citations
4.
5.
Hall, Daniel L., Beverly J. Levine, Janet A. Tooze, et al.. (2022). A spotlight on avoidance coping to manage fear of recurrence among breast cancer survivors in an eHealth intervention. Journal of Behavioral Medicine. 45(5). 771–781. 5 indexed citations
6.
Wagner, Lynne I., Janet A. Tooze, Daniel L. Hall, et al.. (2021). Targeted eHealth Intervention to Reduce Breast Cancer Survivors’ Fear of Recurrence: Results From the FoRtitude Randomized Trial. JNCI Journal of the National Cancer Institute. 113(11). 1495–1505. 46 indexed citations
7.
Saphner, Thomas J., et al.. (2021). Clinical trial participation assessed by age, sex, race, ethnicity, and socioeconomic status. Contemporary Clinical Trials. 103. 106315–106315. 22 indexed citations
8.
Saphner, Thomas J., et al.. (2016). Insights From Building a New National Cancer Institute Community Oncology Research Program Site.. PubMed. 115(4). 191–5. 1 indexed citations
9.
Adams, Sylvia, Robert J. Gray, Sandra Demaria, et al.. (2014). Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199. Journal of Clinical Oncology. 32(27). 2959–2966. 953 indexed citations breakdown →
10.
11.
Chang, Julie, Jae Werndli, Wayne A. Bottner, et al.. (2010). Rituximab and CHOP Chemotherapy Plus GM-CSF for Previously Untreated Diffuse Large B-Cell Lymphoma in the Elderly: A Wisconsin Oncology Network Study. Clinical Lymphoma Myeloma & Leukemia. 10(5). 379–384. 13 indexed citations
12.
Sparano, J. A., Vered Stearns, Silvana Martino, et al.. (2009). Black Race Is Associated with a Worse Outcome in Patients with Hormone Receptor Positive, HER2-Normal Breast Cancer Treated with Adjuvant Chemohormonal Therapy.. Cancer Research. 69(24_Supplement). 37–37. 2 indexed citations
13.
Mulkerin, Daniel, Jordan Berlin, KyungMann Kim, et al.. (2005). A Phase II Trial of Gemcitabine, 5-Fluorouracil and Leucovorin in Advanced Esophageal Carcinoma. Oncology. 69(2). 130–134. 9 indexed citations
14.
Reddy, Kavita S., et al.. (2001). Segmental amplification of 11q23 region identified by flourescence in situ hybridization in four patients with myeloid disorders. Cancer Genetics and Cytogenetics. 126(2). 139–146. 16 indexed citations
15.
Saphner, Thomas J., Edie Weller, Douglass C. Tormey, et al.. (2000). 21-Day Oral Etoposide for Metastatic Breast Cancer. American Journal of Clinical Oncology. 23(3). 258–262. 19 indexed citations
16.
Saphner, Thomas J., Andrea B. Troxel, D C Tormey, et al.. (1993). Phase II study of goserelin for patients with postmenopausal metastatic breast cancer.. Journal of Clinical Oncology. 11(8). 1529–1535. 14 indexed citations
17.
Saphner, Thomas J., Douglass C. Tormey, & Patrick Carey. (1992). Continuous‐infusion 5‐fluorouracil combined with doxorubicin and cyclophosphamide: Feasibility study. Medical and Pediatric Oncology. 20(4). 321–324. 4 indexed citations
18.
Saphner, Thomas J., Douglass C. Tormey, & Mark R. Albertini. (1991). Continuous infusion 5-fluorouracil with escalating doses of intermittent cisplatin and etoposide. A phase I study. Cancer. 68(11). 2359–2362. 6 indexed citations
19.
Saphner, Thomas J., D C Tormey, & Richard Gray. (1991). Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.. Journal of Clinical Oncology. 9(2). 286–294. 319 indexed citations
20.
Saphner, Thomas J., Holly H. Gallion, John R. van Nagell, Richard J. Kryscio, & Roy A. Patchell. (1989). Neurologic complications of cervical cancer. A review of 2261 cases. Cancer. 64(5). 1147–1151. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Grazyna Liebérman Breakdown of academic impact, for papers by Lorenzo Gianni Breakdown of academic impact, for papers by Robert S. Lavey Breakdown of academic impact, for papers by Susan C. Guba Breakdown of academic impact, for papers by H. Richard Alexander Breakdown of academic impact, for papers by Cristian Lolli Breakdown of academic impact, for papers by Lina Tang Breakdown of academic impact, for papers by Stefan Diem Breakdown of academic impact, for papers by Pınar Saip Breakdown of academic impact, for papers by Wei‐Xiang Qi
Rankless by CCL
2026